Melanoma. Il parere dell esperto. V. Ferraresi. Divisione di Oncologia Medica 1
|
|
- Percival Hodges
- 6 years ago
- Views:
Transcription
1 Melanoma Il parere dell esperto V. Ferraresi Divisione di Oncologia Medica 1
2 MELANOMA and ESMO 2017.what happens? New data and updates ADJUVANT THERAPY with CHECKPOINT INHIBITORS (CA trial) AND TARGET THERAPY (BRIM8 and COMBI-AD trials).the immediate future IMMUNOTHERAPY..two is always better than one??.. the goal is (again) the CR!!. new targets!! COMBO TARGET THERAPY (COLUMBUS) a confirmation lesser toxicity? COMBO IMMUNO/TARGET THERAPIES.the future???
3 MELANOMA and ESMO 2017.what happens? New data and updates ADJUVANT THERAPY with CHECKPOINT INHIBITORS (CA ) AND TARGET THERAPY (BRIM8, COMBI-AD)..the immediate future IMMUNOTHERAPY..two is always better than one??.. the goal is (again) the CR!! new targets!! COMBO TARGET THERAPY (COLUMBUS) a confirmation lesser toxicity? COMBO IMMUNO/TARGET THERAPIES.the future???
4 ESMO 2017 and MELANOMA IPI10 vs NIVO3 DABR+TRAM vs placebo VEM vs placebo
5
6 OS data immature BRAF mutated pts: about 40% CA COMBI-AD
7 SUBGROUP ANALYSES COMBI-AD CA
8 EORTC No stratification according to BRAF status HR= 0.86, CI ; P < HR = 0.90, CI ; P = 0.003
9 Only IIIB/IIIC patients
10 Checkmate-238 Nivolumab vs Ipilimumab
11 Is adjuvant checkpoint blockade after resection necessary or it should be reserved wiht the hope of equal benefit for patients who have a relapse with unresectale disease after surgery for stage III or IV melanoma.??
12 CheckMate 915 An Investigational Immuno-therapy Study of Nivolumab Combined With Ipilimumab Compared to Nivolumab by Itself After Complete Surgical Removal of Stage IIIb/c/d or Stage IV Melanoma (NCT ) IPI alone arm eliminated Recruiting Italy partecipation pending.
13 ESMO 2017 MELANOMA ADJUVANT THERAPY with CHECKPOINT INHIBITORS AND TARGET THERAPY Differences in population characteristics (stage, BRAF status): comparisons methodologically not correct BRAF inhibitors alone: is there a future??? BRAFi/MEKi combo (COMBI-AD trial): clear RFS, DMFS and OS benefit in all stages. The new standard for BRAF mutated patients? anti-pd1: Pending OS data q2wks NIVO vs q3wks flat PEMBRO End of adjuvant IPI10mg/kg (FDA approval): more toxic and less active than NIVO, light dose in combo with NIVO in ongoing trials Neoadjuvant + adjuvant treatment with combo immuno or combo target therapy high % of ORR (80-100%) and pcr (40-50%) improve locoregional control?? avoid TLND in pts with palpable nodes??
14 MELANOMA and ESMO 2017.what happens? New data and updates ADJUVANT THERAPY with CHECKPOINT INHIBITORS (CA trial) AND TARGET THERAPY (BRIM8 andcombi-ad trials)..the immediate future IMMUNOTHERAPY..two is always better than one??.. the goal is (again) the CR!!. new targets!! COMBO TARGET THERAPY (COLUMBUS) a confirmation lesser toxicity? COMBO IMMUNO/TARGET THERAPIES.the future???
15 CheckMate 067 (ESMO2017) 17
16 CheckMate 067 (ESMO2017)
17 CA BRAF mutated pts: 31-32%
18 CA
19 Three-year overall survival data based on PD-L1 expression using time-dependent ROC for censored survival data Area- under-the-curve values, as compared with 0.5 (the line of no discrimination), were 0.56 (95% CI, 0.49 to 0.63) in the nivolumab-plus-ipilimumab group (P = 0.09) and 0.57 (95% CI, 0.50 to 0.63) in the nivolumab group (P = 0.04), which indicate that the level of tumor PD-L1 expression alone is a poor predictive biomarker of overall survival
20 NIVOLUMAB/IPILIMUMAB combo What to say awaiting the regimen? PD-L1: starting point for discussion with patients for combo IPI/NIVO versus NIVO (if we don t need the response to palliate symptoms and if you have favorite sites of disease ) BRAF mutation status and combo immunotherapy IPI/NIVO: we need more data on patients characteristics (bias of selection?) no head-to-head comparison versus combo target therapy role of subsequent lines of therapy toxicity as a point for discussion with patients (% G3-4 toxicities)
21 Classifying Cancers Based ont-cell Infiltration and PD-L1 - Melanoma ~40% ~40% ~20% ~1% Teng MWL, Cancer Research 2015
22 Potential Role of LAG-3 in T-Cell Exhaustion and Anti PD-1 Resistance LAG-3 regulates a checkpoint pathway that limits the activity of T cells 1 LAG-3 and PD-1 receptors are overexpressed and/or coexpressed on tumor-infiltrating lymphocytes in melanoma 2,3 I-O therapy naive: LAG-3 may limit I-O response + Nivolumab + Relatlimab PD-1 PD-L1 Tumor or other infiltrating cell Effector CD4 + /CD8 + T cell I-O therapy experienced: LAG-3 may contribute to resistance + Antigen LAG-3 PD-1 MHC II +Nivolumab Acquired resistance PD-L1 PD-1 MHC II LAG-3 + Nivolumab + Relatlimab Nivolumab Relatlimab (BMS /anti LAG-3) I-O, immuno-oncology; MHC II, major histocompatibility complex class II; PD-1, programmed death-1; PD- L1, programmed death ligand Grosso JF et al. J Clin Invest. 2007;117: Goding SR et al. J Immunol. 2013;190: Taube JM et al. Clin Cancer Res. 2015;21:
23 Relatlimab (anti-lag3) + Nivolumab PD-1/PD-L1 resistant/refractory melanoma pts Mel Prior PD-(L)1 a t All Patients a N = 270 ORR, n (%) c All n = 61 7 (11.5) d 95% CI 4.7, 22 BOR, n (%) c LAG-3 1% b n = 33 6 (18) d 7, 35.5 CR 1 (1.6) 1 (3.0) PR 6 (9.8) d 5 (15) d SD 23 (38) 15 (45) PD 25 (41) 8 (24) Clinical progression e 6 (9.8) 4 (12) DCR (CR + PR + SD), n (%) c 30 (49) 95% CI 36, (64) 45, 80 PD1/PD-L1 resistant patients (46% PD as best response, 77% > 2 prior lines) Any Grade n (%) Grade 3 4 n (%) Any TRAE b 137 (51) 27 (10) TRAEs in 5% of patients Fatigue 30 (11) 0 Pruritus 19 (7.0) 0 Diarrhea 18 (6.7) 3 (1.1) Arthralgia 17 (6.3) 0 Infusion-related reaction 15 (5.6) 0 Any serious TRAE b 18 (6.7) 12 (4.4) Serious TRAEs in > 1 patient Colitis 4 (1.5) 3 (1.1) Pneumonitis 2 (0.7) 2 (0.7) Myocarditis c 2 (0.7) 0 Pyrexia 2 (0.7) 0 Any TRAE leading to discontinuation b 11 (4.1) 8 (3.0) LAG-3 expression ( 1%) enriched for response Median duration of response was not reached (range, 0.1+ to 39+) 35
24 Best percent change in sum of target RELATLIMAB PD-1/PD-L1 resistant/refractory melanoma pts Best Change in Target Lesion Size by LAG-3 and PD-L1 Expression lesion diameters from baseline a,b LAG-3 1% n = 29 45% with tumor reduction LAG-3 < 1% n = 17 24% with tumor reduction LAG-3 Unknown n = 8 13% with tumor reduction Pink: PD-L1 1% Blue: PD-L1 < 1% Gray: PD-L1 unknown a Six patients with clinical progression prior to their first scan and 1 with PD due to a new symptomatic brain metastasis prior to getting full scans were not included. b One patient with best change from baseline > 30% had a best response of SD. 37
25 ECHO-202/KEYNOTE-037 BRAF mut: 29%; M1c; 55%; Liver: 40%
26
27 ECHO-301/KEYNOTE 352 phase III trial ongoing (fully accrued)
28 MELANOMA and ESMO 2017.what happens? New data and updates ADJUVANT THERAPY with CHECKPOINT INHIBITORS (CA trial) AND TARGET THERAPY (BRIM8 andcombi-ad trials) the immediate future IMMUNOTHERAPY..two is always better than one??.. the goal is (again) the CR!!. new targets!! COMBO TARGET THERAPY (COLUMBUS) a confirmation lesser toxicity? COMBO IMMUNO/TARGET THERAPIES.the future???
29
30 COLUMBUS ESM Lower incidence of pyrexia and dermatological toxicity - Higher incidence of hepatic toxicity not confirmed in phase III trial COMBI-d 1 COMBI-v 2 cobrim 3 Dabrafenib + Dabrafenib + Vemurafenib + Study Agent(s) Dabrafenib Vemurafenib Vemurafenib Trametinib Trametinib Cobimetinib Patients, n (study arm) BRAF + MEK 209 Inhibitor 211 Combination 350 Treatment AEs of interest, % CuSCC/KA Phase 3 Studies: 2 Adverse 9 Events of 1 Special Interest Skin papilloma Hyperkeratosis Photosensitivity reaction Decreased ejection fraction Hypertension Chorioretinopathy < 1 < 1 1 < 1 12 < 1 Hand-foot syndrome b Increased ALT Increased AST Retinal detachment QT interval prolongation
31 (1% due to tox)
32
33
34 MELANOMA and ESMO 2017.what happens? New data and updates ADJUVANT THERAPY with CHECKPOINT INHIBITORS (CA trial) AND TARGET THERAPY (BRIM8 andcombi-ad trials) the immediate future IMMUNOTHERAPY..two is always better than one??.. the goal is (again) the CR!! new targets!! COMBO TARGET THERAPY (COLUMBUS) a confirmation lesser toxicity? COMBO IMMUNO/TARGET THERAPIES.the future???
35 TARGETED THERAPIES AND IMMUNOTHERAPIES HOW TO USE THESE AGENTS TOGETHER? SEQUENCES??? after progression? at predefinite time? METASTATIC MELANOMA BRAF MUTATED DISEASE CONCURRENT COMBINATIONS???
36 BRAF inhibitors and immune system
37
38
39
40
41 KEYNOTE022 Phase 2: Combination Pembrolizumab + Dabrafenib + Trametinib Study Design Key eligibility criteria Unresectable or metastatic stage IV BRAF V600E/K mutant melanoma No prior therapy ECOG performance status 0-1 N = 120 Randomised 1:1 Stratified by: ECOG performance status (0 vs 1) LDH: > 1.1 ULN vs 1.1 ULN Pembrolizumab 2 mg/kg Q3W + dabrafenib 150 mg BID + trametinib 2 mg QD Placebo Q3W + dabrafenib 150 mg BID + trametinib 2 mg QD Treatment until disease progression, intolerable toxicity, investigator decision, or (for pembrolizumab) 24 months a Primary endpoint: PFS Secondary endpoints: ORR, DOR, OS ECOG, Eastern Cooperative Oncology Group; LDH, lactate dehydrogenase; ULN, upper limit of normal. a Patients experiencing a confirmed CR after 6 months may discontinue pembrolizumab after receiving 2 doses beyond initial CR but may continue treatment with dabrafenib and trametinib. Long GV, et al. J Clin Oncol. 2016;34(suppl) [abstract TPS9596].
42 Different Profiles of Treatment: Facts on Efficacy Immunotherapies: Limited by non-responders Long-term plateau of OS demonstrated for anti-ctla4 and anti-pd-1 Efficacy possible beyond discontinuation No condition identified for efficacy (PD-L1)? Targeted therapies: Efficacy conditioned on mutation BRAF 3 years OS plateau demonstrated for D T Limited by resistance No clear demonstration that can be discontinued So far No predictive marker for choice of frontline treatment No marker for safe discontinuation No marker for best selection of combination, or order of sequencing (ONGOING TRIALS) Optimal scheduling for combo immunotherapies awaiting (IPI light )
43 Different Profiles of Treatment: Perceptions... Truth is different than perception Immunotherapies: Natural : exploit endogenous immune system to eradicate cancer Slow Exclude fast progressions Long response Targeted therapies: All treatments are less active when the disease is aggressive and fast (eg, high LDH) Artificial : precision/perzonalized medicine Fast Anti-PD-1+CTLA4 inhibitors work nearly as fast as targeted therapies More active in case of fast progression Resistance sooner or later Targeted therapies can provide very long survival Different profiles of toxicities ( and combo TT/IT) What to do? AWAIT THE RESULTS OF CLINICAL TRIALS! Outside an investigational trial we must still be guided by patients and disease characteristics
44 Melanoma treatment Grazie
Immunotherapy in the Adjuvant Setting for Melanoma: What You Need to Know
Immunotherapy in the Adjuvant Setting for Melanoma: What You Need to Know Jeffrey Weber, MD, PhD Laura and Isaac Perlmutter Cancer Center NYU Langone Medical Center New York, New York What Is the Current
More informationImmunotherapy in Unresectable or Metastatic Melanoma: Where Do We Stand? Sanjiv S. Agarwala, MD St. Luke s Cancer Center Bethlehem, Pennsylvania
Immunotherapy in Unresectable or Metastatic Melanoma: Where Do We Stand? Sanjiv S. Agarwala, MD St. Luke s Cancer Center Bethlehem, Pennsylvania Overview Background Immunotherapy clinical decision questions
More informationMelanoma: From Chemotherapy to Targeted Therapy and Immunotherapy. What every patient needs to know. James Larkin
Melanoma: From Chemotherapy to Targeted Therapy and Immunotherapy What every patient needs to know James Larkin Melanoma Therapy 1846-2017 Surgery 1846 Cytotoxic Chemotherapy 1946 Checkpoint Inhibitors
More informationSummary... 2 MELANOMA AND OTHER SKIN TUMOURS... 3
ESMO 2016 Congress 7-11 October, 2016 Copenhagen, Denmark Table of Contents Summary... 2 MELANOMA AND OTHER SKIN TUMOURS... 3 Long-term results show adjuvant therapy with ipilimumab improves OS in high
More informationImmunotherapy of Melanoma Sanjiv S. Agarwala, MD
Immunotherapy of Melanoma Sanjiv S. Agarwala, MD Professor of Medicine Temple University School of Medicine Chief, Oncology & Hematology St. Luke s Cancer Center, Bethlehem, PA Overview Metastatic Melanoma
More informationMedical Treatment for Melanoma Sanjiv S. Agarwala, MD
Medical Treatment for Melanoma Sanjiv S. Agarwala, MD Professor of Medicine Temple University School of Medicine Chief, Oncology & Hematology St. Luke s Cancer Center, Bethlehem, PA Disclosures None Overview
More informationPhase 1 Study Combining Anti-PD-L1 (MEDI4736) With BRAF (Dabrafenib) and/or MEK (Trametinib) Inhibitors in Advanced Melanoma
Phase 1 Study Combining Anti-PD-L1 (MEDI4736) With BRAF (Dabrafenib) and/or MEK (Trametinib) Inhibitors in Advanced Melanoma Abstract #3003 Ribas A, Butler M, Lutzky J, Lawrence D, Robert C, Miller W,
More informationNew Systemic Therapies in Advanced Melanoma
New Systemic Therapies in Advanced Melanoma Sanjay Rao, MD FRCPC Medical Oncologist (BCCA-CSI) Clinical Assistant Professor, UBC Faculty of Medicine SON Fall Update October 22, 2016 Disclosures Equity
More informationMelanoma: Immune checkpoints
ESMO Preceptorship Programme Immuno-Oncology Siena, July 04-05, 2016 Melanoma: Immune checkpoints Michele Maio Medical Oncology and Immunotherapy-Department of Oncology University Hospital of Siena, Istituto
More informationIII Sessione I risultati clinici
10,30-13,15 III Sessione I risultati clinici Moderatori: Michele Maio - Valter Torri 10,30-10,45 Melanoma: anti CTLA-4 Vanna Chiarion Sileni Vanna Chiarion Sileni IOV-IRCCS,Padova Vanna.chiarion@ioveneto.it
More informationImmunotherapy for the Treatment of Melanoma. Marlana Orloff, MD Thomas Jefferson University Hospital
Immunotherapy for the Treatment of Melanoma Marlana Orloff, MD Thomas Jefferson University Hospital Disclosures Immunocore and Castle Biosciences, Consulting Fees I will be discussing non-fda approved
More informationCurrent Trends in Melanoma Theresa Medina, MD UCD Cutaneous Oncology
Current Trends in Melanoma Theresa Medina, MD UCD Cutaneous Oncology Overview Melanoma incidence and prevention Approach to surgical management of early melanoma Landscape of Advanced Melanoma Therapy
More informationNew Therapeutic Approaches to Malignant Melanoma
2018 Master Class for Oncologists New Therapeutic Approaches to Malignant Melanoma F. Stephen Hodi, M.D. Dana-Farber Cancer Institute, Boston, MA Disclosure I have nothing to disclose. Off Label/Investigational
More informationMELANOMA METASTASICO: NUEVAS COMBINACIONES. Dr Ana Arance MD PhD Oncología Médica Hospital Clínic Barcelona
MELANOMA METASTASICO: NUEVAS COMBINACIONES Dr Ana Arance MD PhD Oncología Médica Hospital Clínic Barcelona Summary of OS accross clinical trials in patients with metastatic melanoma Ugurel et al. Eur J
More informationMELANOMA: THE BEST OF THE YEAR Dott.ssa Silvia Quadrini UOC Oncologia ASL Frosinone
MELANOMA: THE BEST OF THE YEAR 2018 Dott.ssa Silvia Quadrini UOC Oncologia ASL Frosinone The Best of the Year 2018: MELANOMA CHIRURGIA TERAPIA ADIUVANTE TERAPIA PER MALATTIA AVANZATA The Best of the Year
More informationNew paradigms for treating metastatic melanoma
New paradigms for treating metastatic melanoma Paul B. Chapman, MD Melanoma Clinical Director Melanoma and Immunotherapeutics Service Memorial Sloan Kettering Cancer Center, New York 20 th Century Overall
More informationUpdate on Immunotherapy in Advanced Melanoma. Ragini Kudchadkar, MD Assistant Professor Winship Cancer Institute Emory University Sea Island 2017
Update on Immunotherapy in Advanced Melanoma Ragini Kudchadkar, MD Assistant Professor Winship Cancer Institute Emory University Sea Island 2017 1 Outline Adjuvant Therapy Combination Immunotherapy Single
More informationTerapia Immunomodulante e Target Therapies nel Trattamento del Melanoma Metastatico
Terapia Immunomodulante e Target Therapies nel Trattamento del Melanoma Metastatico Pier Francesco Ferrucci Direttore, Unità di Oncologia Medica del Melanoma Istituto Europeo di Oncologia - Milano Pisa,
More informationImmunotherapy for Renal Cell Carcinoma. James Larkin
Immunotherapy for Renal Cell Carcinoma James Larkin Disclosures Institutional research support: BMS, MSD, Novartis, Pfizer Consultancy (all non-remunerated): Eisai, BMS, MSD, GSK, Pfizer, Novartis, Roche/Genentech
More informationASCO 2014: The Future is Here. What I Will Talk About. George W. Sledge MD Stanford University School of Medicine
ASCO 214: The Future is Here George W. Sledge MD Stanford University School of Medicine What I Will Talk About Two paths to a Cure Slicing the pie MelMng the snowflake The Past Isn t Dead Improving PaMent
More informationMelanoma Clinical Trials and Real World Experience
Melanoma Clinical Trials and Real World Experience Paul Lorigan University of Manchester Manchester, UK www.christie.nhs.uk/melanoma Melanoma Bridge, Naples 214 New Benchmarks for Phase II Trials OS at
More informationMelanoma in Focus: Update on Novel Therapy, Emerging Agents, and Optimizing Patient Care Presentation 1
Presentation 1 The following is a transcript from a web-based CME -certified multimedia activity. Interactivity applies only when viewing the activity online. This activity is supported by educational
More informationOverall Survival in COLUMBUS: A Phase 3 Trial of Encorafenib (ENCO) Plus Binimetinib (BINI) vs Vemurafenib (VEM) or ENCO in BRAF-Mutant Melanoma
Overall Survival in COLUMBUS: A Phase 3 Trial of Encorafenib (ENCO) Plus Binimetinib (BINI) vs Vemurafenib () or ENCO in BRAF-Mutant Melanoma, Paolo A. Ascierto, Helen J. Gogas, Ana Arance, Mario Mandala,
More informationCombination Approaches in Melanoma: A Balancing Act
Combination Approaches in Melanoma: A Balancing Act Antoni Ribas, MD, PhD Jonsson Comprehensive Cancer Center University of California Los Angeles Los Angeles, California Advances in the Treatment of Metastatic
More informationII sessione. Immunoterapia oltre la prima linea. Alessandro Tuzi ASST Sette Laghi, Varese
II sessione Immunoterapia oltre la prima linea Alessandro Tuzi ASST Sette Laghi, Varese AGENDA Immunotherapy post-chemo ( true 2/3L ) Immunotherapy in oncogene addicted NSCLC (yes/no? when?) Immunotherapy
More informationImmunotherapy for Metastatic Malignant Melanoma. Dr Daniel A Vorobiof Sandton Oncology Centre Johannesburg
Immunotherapy for Metastatic Malignant Melanoma Dr Daniel A Vorobiof Sandton Oncology Centre Johannesburg Survival in Melanoma by Stage Proportion Surviving 1.0 0.9 0.8 0.7 0.6 0.5 0.4 0.3 0.2 0.1 Stage
More informationImmunotherapy for NSCLC: Current State of the Art and Future Directions. H. Jack West, MD Swedish Cancer Institute Seattle, Washington, United States
Immunotherapy for NSCLC: Current State of the Art and Future Directions H. Jack West, MD Swedish Cancer Institute Seattle, Washington, United States Which of the following statements regarding immunotherapy
More informationImmunotherapy for Melanoma. Michael Postow, MD Melanoma and Immunotherapeutics Service Memorial Sloan Kettering Cancer Center
Immunotherapy for Melanoma Michael Postow, MD Melanoma and Immunotherapeutics Service Memorial Sloan Kettering Cancer Center Conflicts of Interest Bristol-Myers Squibb: -Research support -Participated
More information6/7/16. Melanoma. Updates on immune checkpoint therapies. Molecularly targeted therapies. FDA approval for talimogene laherparepvec (T- VEC)
Melanoma John A Thompson MD July 17, 2016 Featuring: Updates on immune checkpoint therapies Molecularly targeted therapies FDA approval for talimogene laherparepvec (T- VEC) 1 Mechanism of ac-on of Ipilimumab
More informationNSCLC: immunotherapy as a first-line treatment. Paolo Bironzo Oncologia Polmonare AOU S. Luigi Gonzaga Orbassano (To)
NSCLC: immunotherapy as a first-line treatment Paolo Bironzo Oncologia Polmonare AOU S. Luigi Gonzaga Orbassano (To) The 800-pound gorilla Platinum-based chemotherapy is the SOC for 1st-line therapy in
More informationWhat we learned from immunotherapy in the past years
What we learned from immunotherapy in the past years Paolo A. Ascierto, MD Unit Melanoma, Cancer Immunotherapy and Innovative Therapies Istituto Nazionale Tumori Fondazione G. Pascale, Napoli, Italy Disclosure
More informationASCO / COLUMBUS ENCORE PRESENTATION June 4, 2018
ASCO / COLUMBUS ENCORE PRESENTATION June 4, 2018 SAFE HARBOR STATEMENT Forward-looking statements made in the course of this presentation are made pursuant to the safe harbor provisions of the Private
More informationAmerikanischer Krebskongress 2018
Congress-Lightning Amerikanischer Krebskongress 218 Dermatoonkologie Prof. Dr. Ralf Gutzmer, Hannover Melanom adjuvant Melanom palliativ Nicht-melanozytäre Hauttumore Adjuvant Therapy With Nivolumab Versus
More informationMelanoma: Therapeutic Progress and the Improvements Continue
Melanoma: Therapeutic Progress and the Improvements Continue David W. Ollila, MD Professor of Surgery Jesse and James Millis Professor of Melanoma Research May 20, 2016 Disclosures: NONE Outline 2016 Therapeutic
More informationfor patients with ECOG PS 0-1 as indicated in the CheckMate-067 trial. Upon reconsideration of the Initial Recommendation, perc noted PAG s feedback requesting guidance on extrapolating eligibility to
More informationUnmet Need Mucosal and Uveal Melanoma
Unmet Need Mucosal and Uveal Melanoma Matteo Carlino Crown Princess Mary Cancer Centre Westmead and Blacktown Hospitals Melanoma Institute Australia The University of Sydney. Cutaneous Overall Survival
More informationTreatment and management of advanced melanoma: Paul B. Chapman, MD Melanoma Clinical Director, Melanoma and Immunotherapeutics Service MSKCC
Treatment and management of advanced melanoma: 2018 Paul B. Chapman, MD Melanoma Clinical Director, Melanoma and Immunotherapeutics Service MSKCC Disclosure Paul B. Chapman, MD Nothing to disclose. Off
More informationImmunotherapy for Melanoma. Caroline Robert, MD, PhD Gustave Roussy and Université Paris Sud Villejuif, France
Immunotherapy for Melanoma Caroline Robert, MD, PhD Gustave Roussy and Université Paris Sud Villejuif, France Overall Survival for Metastatic Melanoma Proportion Alive 1.0 0.8 0.6 0.4 0.2 Survival data
More informationTargeted Therapies in Melanoma
Mutations and Targets Targeted Therapies in Melanoma ckit NRAS
More informationThe information in this activity is intended for healthcare professionals based outside of the United States. This activity may contain information
The information in this activity is intended for healthcare professionals based outside of the United States. This activity may contain information on products outside the approved indications where you
More informationManagement of Brain Metastases Sanjiv S. Agarwala, MD
Management of Brain Metastases Sanjiv S. Agarwala, MD Professor of Medicine Temple University School of Medicine Chief, Oncology & Hematology St. Luke s Cancer Center, Bethlehem, PA, USA Incidence (US):
More informationImmunoterapia e melanoma maligno metastatico: siamo partiti da li. Vanna Chiarion Sileni Istituto Oncologico Veneto
Immunoterapia e melanoma maligno metastatico: siamo partiti da li Vanna Chiarion Sileni Istituto Oncologico Veneto Vanna.chiarion@iov.veneto.it Metastatic Melanoma Available Treatment: 197 217 Zelboraf
More informationImmunotherapy, an exciting era!!
Immunotherapy, an exciting era!! Yousef Zakharia MD University of Iowa and Holden Comprehensive Cancer Center Alliance Meeting, Chicago November 2016 Presentation Objectives l General approach to immunotherapy
More informationNew treatments in melanoma
New treatments in melanoma Paolo A. Ascierto, MD Istituto Nazionale Tumori Fondazione G. Pascale, Naples, Italy Meta-analysis of Phase II cooperative group trials in metastatic stage IV melanoma to determine
More informationCheckMate 012: Safety and Efficacy of First Line Nivolumab and Ipilimumab in Advanced Non-Small Cell Lung Cancer
CheckMate 12: Safety and Efficacy of First Line Nivolumab and Ipilimumab in Advanced Non-Small Cell Lung Cancer Abstract 31 Hellmann MD, Gettinger SN, Goldman J, Brahmer J, Borghaei H, Chow LQ, Ready NE,
More informationThe Really Important Questions Current Immunotherapy Trials are Not Answering
The Really Important Questions Current Immunotherapy Trials are Not Answering David McDermott, MD Beth Israel Deaconess Medical Center Dana Farber/Harvard Cancer Center Harvard Medical School PD-1 Pathway
More informationImmunotherapy Treatment Developments in Medical Oncology
Immunotherapy Treatment Developments in Medical Oncology A/Prof Phillip Parente Director Cancer Services Eastern Health Executive MOGA ATC Medical Oncology RACP www.racpcongress.com.au Summary of The Desired
More informationImmunotherapies in melanoma: regulatory perspective. Jorge Camarero (AEMPS)
Immunotherapies in melanoma: regulatory perspective Jorge Camarero (AEMPS) Challenges for the approval of anti-cancer immunotherapeutic drugs EMA-CDDF joint meeting, London 4-5 February 2016 disclaimers
More informationRevolution in der adjuvanten Therapie des Melanoms? Was bleibt? Was wird sich verändern?
Revolution in der adjuvanten Therapie des Melanoms? Was bleibt? Was wird sich verändern? Dr. Peter Mohr, Elbeklinikum Buxtehude Hautkrebszentrum Oktober 217 Approved treatments for melanoma in the adjuvant
More informationImmune checkpoint blockade in lung cancer
Immune checkpoint blockade in lung cancer Raffaele Califano Department of Medical Oncology The Christie and University Hospital of South Manchester, Manchester, UK Outline Background Overview of the data
More informationOut of 129 patients with NSCLC treated with Nivolumab in a phase I trial, the OS rate at 5-y was about 16 %, clearly higher than historical rates.
6th Meeting on external quality assessment in molecular pathology, Naples, May 12-13, 2017 Overview of clinical development of checkpoint inhibitors in solid tumors Pr Jaafar BENNOUNA University of Nantes
More informationPTAC meeting held on 5 & 6 May (minutes for web publishing)
PTAC meeting held on 5 & 6 May 2016 (minutes for web publishing) PTAC minutes are published in accordance with the Terms of Reference for the Pharmacology and Therapeutics Advisory Committee (PTAC) and
More informationOptimizing Immunotherapy New Approaches, Biomarkers, Sequences and Combinations Immunotherapy in the clinic Melanoma
Optimizing Immunotherapy New Approaches, Biomarkers, Sequences and Combinations Immunotherapy in the clinic Melanoma Dr. J.L.Manzano S. Oncología Médica H. Germans Trias i Pujol, ICO-Badalona PRBB Auditorium,
More informationApproaches To Treating Advanced Melanoma
Approaches To Treating Advanced Melanoma Suraj Venna, MD Medical Director, Melanoma and Cutaneous Oncology Inova Schar Cancer Institute Associate Professor, VCU Fairfax VA Disclosures No relevant disclosures
More informationChemotherapy and Immunotherapy in Combination Non-Small Cell Lung Cancer (NSCLC)
Chemotherapy and Immunotherapy in Combination Non-Small Cell Lung Cancer (NSCLC) Jeffrey Crawford, MD George Barth Geller Professor for Research in Cancer Co-Program Leader, Solid Tumor Therapeutics Program
More informationMariano Provencio Servicio de Oncología Médica Hospital Universitario Puerta de Hierro. Immune checkpoint inhibition in DLBCL
Mariano Provencio Servicio de Oncología Médica Hospital Universitario Puerta de Hierro Immune checkpoint inhibition in DLBCL Immunotherapy: The Cure is Inside Us Our immune system prevents or limit infections
More informationLa revolución de la inmunoterapia: dónde la posicionamos? Javier Puente, MD, PhD
La revolución de la inmunoterapia: dónde la posicionamos? Javier Puente, MD, PhD Hospital Universitario Clinico San Carlos Medical Oncology Department Thoracic & Urological Cancer Unit Complutense University
More informationArray BioPharma Jefferies 2016 Global Healthcare Conference. June 9, 2016
Array BioPharma Jefferies 216 Global Healthcare Conference June 9, 216 Safe Harbor Statement 2 Forward-looking statements made in the course of this presentation are made pursuant to the safe harbor provisions
More informationPresentation Number: LBA18_PR. Lecture Time: 09:15-09:27. Speakers: Heinz-Josef J. Lenz (Los Angeles, US) Background
LBA18_PR - Durable Clinical Benefit With Nivolumab (NIVO) Plus Low-Dose Ipilimumab (IPI) as First-Line Therapy in Microsatellite Instability-High/Mismatch Repair Deficient (MSI-H/dMMR) Metastatic Colorectal
More informationImmunotherapy for Breast Cancer. Aurelio B. Castrellon Medical Oncology Memorial Healthcare System
Immunotherapy for Breast Cancer Aurelio B. Castrellon Medical Oncology Memorial Healthcare System Conflicts Research support : Cascadian therapeutics, Puma biotechnology, Odonate therapeutics, Pfizer,
More informationWeitere Kombinationspartner der Immunotherapie
1 Weitere Kombinationspartner der Immunotherapie Rolf Stahel University Hospital of Zürich Zürich, 9.12.216 2 Immunotherapy in a multimodality approach NSCLC Advanced disease Checkpoint inhibitors for
More informationCheckpoint regulators a new class of cancer immunotherapeutics. Dr Oliver Klein Medical Oncologist ONJCC Austin Health
Checkpoint regulators a new class of cancer immunotherapeutics Dr Oliver Klein Medical Oncologist ONJCC Austin Health Cancer...Immunology matters Anti-tumour immune response The participants Dendritc cells
More informationInmunoterapia en cáncer renal metastásico: redefiniendo el tratamiento de segunda línea
Inmunoterapia en cáncer renal metastásico: redefiniendo el tratamiento de segunda línea Daniel Castellano Oncología Médica. Unidad de Tumores Genito-Urinarios Hospital Universitario 12 de Octubre I + 12
More informationCost-effectiveness of nivolumab with ipilimumab (Opdivo with Yervoy ) for the treatment of advanced (unresectable or metastatic) melanoma.
Cost-effectiveness of nivolumab with ipilimumab (Opdivo with Yervoy ) for the treatment of advanced (unresectable or metastatic) melanoma. The National Centre for Pharmacoeconomics (NCPE) has issued a
More informationMEETING SUMMARY ESMO 2018, Munich, Germany. Dr. Jenny Seligmann University of Leeds, UK HIGHLIGHTS ON COLORECTAL CANCER
MEETING SUMMARY ESMO 2018, Munich, Germany Dr. Jenny Seligmann University of Leeds, UK HIGHLIGHTS ON COLORECTAL CANCER DISCLAIMER Please note: The views expressed within this presentation are the personal
More informationBristol-Myers Squibb, Braine-l Alleud, Belgium; 12 MD Anderson Cancer Center, Houston, TX, USA
3531 Combination of nivolumab (NIVO) + ipilimumab (IPI) in the treatment of patients (pts) with deficient DNA mismatch repair (dmmr)/high microsatellite instability (MSI-H) metastatic colorectal cancer
More informationBreakthrough and Landscape of Acral and Mucosal Melanomas. Jun Guo. M.D., Ph.D Peking University Cancer Hospital & Institute
Breakthrough and Landscape of Acral and Mucosal Melanomas Jun Guo. M.D., Ph.D Peking University Cancer Hospital & Institute Current status of advanced melanoma Current status of advanced MM Targeted therapy
More informationIMMUNOTHERAPY FOR GASTROINTESTINAL CANCERS
IMMUNOTHERAPY FOR GASTROINTESTINAL CANCERS Dr Elizabeth Smyth Cambridge University Hospitals NHS Foundation Trust ESMO Gastric Cancer Preceptorship Valencia 2018 DISCLOSURES Honoraria for advisory role
More informationMelanoma: novità ESMO 2017
Melanoma: novità ESMO 2017 Vincenzo Picone Istituto dermopatico dell Immacolata (IDI) AGENDA Metastatico CheckMate 067 Adiuvante LBA7_PR - BRIM8: a randomized, double-blind, placebo-controlled study of
More informationImmune Checkpoint Inhibitors for Lung Cancer William N. William Jr.
Immune Checkpoint Inhibitors for Lung Cancer William N. William Jr. Diretor de Onco-Hematologia Hospital BP, A Beneficência Portuguesa Non-Small Cell Lung Cancer PD-1/PD-L1 Inhibitors in second-line therapy
More informationNivolumab in Patients With DNA Mismatch Repair Deficient/Microsatellite Instability High Metastatic Colorectal Cancer: Update From CheckMate 142
Nivolumab in Patients With DNA Mismatch Repair Deficient/Microsatellite Instability High Metastatic Colorectal Cancer: Update From CheckMate 142 Abstract #519 Overman MJ, Lonardi S, Leone F, McDermott
More informationOvercoming Toxicities Associated with Novel Checkpoint Inhibitor Immunotherapy. Tara C. Gangadhar, MD Assistant Professor of Medicine ICI Boston 2016
Overcoming Toxicities Associated with Novel Checkpoint Inhibitor Immunotherapy Tara C. Gangadhar, MD Assistant Professor of Medicine ICI Boston 2016 Overcoming toxicity A new context for evaluating toxicity
More informationUpdate on Melanoma Treatment. Tara C Mitchell, MD
Update on Melanoma Treatment Tara C Mitchell, MD Overview Immune therapy update Targeted therapy update New concepts in treating melanoma What is the immune system? A complex network of protective cells
More informationImmunotherapy in the clinic. Lung Cancer. Marga Majem 20 octubre 2017
Immunotherapy in the clinic. Lung Cancer Marga Majem 20 octubre 2017 mmajem@santpau.cat Immunotherapy in the clinic. Lung Cancer Agenda Where we come from? Immunotherapy in Second line Immunotherapy in
More informationReview of immunotherapy in melanoma
Review of immunotherapy in melanoma Surein Arulananda, 1,2,3 Elizabeth Blackley, 1 Jonathan Cebon 1,2,3 1. Department of Medical Oncology, Austin Health, Heidelberg, Victoria, Australia. 2. Cancer Immunobiology
More informationOverview: Immunotherapy in CNS Metastases
Overview: Immunotherapy in CNS Metastases Manmeet Ahluwalia, MD, FACP Miller Family Endowed Chair in Neuro-Oncology Director Brain Metastasis Research Program Cleveland Clinic Disclosures Consultant- Monteris
More informationpcodr EXPERT REVIEW COMMITTEE (perc) INITIAL RECOMMENDATION
pcodr EXPERT REVIEW COMMITTEE (perc) INITIAL RECOMMENDATION The CADTH pan-canadian Oncology Drug Review (pcodr) was established by Canada s provincial and territorial M inistries of Health (with the exception
More informationThe next wave of successful drug therapy strategies in HER2-positive breast cancer. Hans Wildiers University Hospitals Leuven Belgium
The next wave of successful drug therapy strategies in HER2-positive breast cancer Hans Wildiers University Hospitals Leuven Belgium Trastuzumab in 1st Line significantly improved the prognosis of HER2-positive
More informationMetastatic NSCLC: Expanding Role of Immunotherapy. Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian
Metastatic NSCLC: Expanding Role of Immunotherapy Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian Disclosures: No relevant disclosures Please note that some of the studies reported in
More informationThe Immunotherapy of Oncology
The Immunotherapy of Oncology The 30-year Overnight Success Story M Avery, BIOtech Now 2014 Disclosures: Geoffrey R. Weiss, M.D. None The History A. Chekov: It has long been noted that the growth of malignant
More informationIl ruolo di PD-L1 (42%) tra la prima e la seconda linea di trattamento
Il ruolo di PD-L1 (42%) tra la prima e la seconda linea di trattamento Alessia Pochesci Divisione di Oncologia Toracica Istituto Europeo di Oncologia, Milano Tutor: Prof.ssa Silvia Novello Dott.ssa Chiara
More informationEvolving Treatment Strategies in the Management of Metastatic Melanoma: Novel Therapies for Improved Patient Outcomes. Disclosures
Evolving Treatment Strategies in the Management of Metastatic Melanoma: Novel Therapies for Improved Patient Outcomes Fall Managed Care Forum November 11, 2016 Matthew Taylor, M.D. Disclosures Consulting/Advisory
More informationCheckpoint Regulators Cancer Immunotherapy takes centre stage. Dr Oliver Klein Department of Medical Oncology 02 May 2015
Checkpoint Regulators Cancer Immunotherapy takes centre stage Dr Oliver Klein Department of Medical Oncology 02 May 2015 Adjuvant chemotherapy improves outcome in early breast cancer FDA approval of Imatinib
More informationRecent Advances in Lung Cancer: Updates from ASCO Updates from ESMO, AACR and ASCO
Recent Advances in Lung Cancer: Updates from ASCO 2018 Updates from ESMO, AACR and ASCO Charu Aggarwal, MD, MPH Assistant Professor of Medicine Division of Hematology-Oncology Abramson Cancer Center University
More informationAppendices. Appendix A Search terms
Appendices Appendix A Search terms Database Search terms Medline 1. Ipilimumab; 2. MDX-010; 3. MDX-101; 4. Yervoy; 5. BMS-734016; 6. Nivolumab; 7. ONO-4538; 8. BMS-936558; 9. MDX-1106; 10. Opdivo; 11.
More informationYoung Kwang Chae 1,2,3*, Ayush Arya 1, Wade Iams 3, Marcelo R. Cruz 1, Sunandana Chandra 1,2,3, Jaehyuk Choi 2,3 and Francis Giles 1,2,3
Chae et al. Journal for ImmunoTherapy of Cancer (2018) 6:39 https://doi.org/10.1186/s40425-018-0349-3 REVIEW Current landscape and future of dual anti- CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer;
More informationONCOS-102 in melanoma Dr. Alexander Shoushtari. 4. ONCOS-102 in mesothelioma 5. Summary & closing
ONCOS-102 in melanoma Dr. Alexander Shoushtari 4. ONCOS-102 in mesothelioma 5. Summary & closing 1 Preliminary data from C824 Activating the Alexander Shoushtari, MD Assistant Attending Physician Melanoma
More informationCutaneous melanoma: new developments for 2018
Cutaneous melanoma: new developments for 2018 and beyond KIM MARGOLIN, M.D., FASCO CITY OF HOPE MEDICAL ONCOLOGY CORONADO, CALIFORNIA SEPTEMBER 20, 2018 DISCLOSURE Consultant for ImaginAb, Nektar Therapeutics,
More informationImmunotherapies for Advanced NSCLC: Current State of the Field. H. Jack West Swedish Cancer Institute Seattle, Washington
Immunotherapies for Advanced NSCLC: Current State of the Field H. Jack West Swedish Cancer Institute Seattle, Washington Nivolumab in Squamous NSCLC Chemo-pretreated (1 st line) Adv squamous NSCLC N =
More informationImmunoterapia di 1 linea Evidenze e Prospettive Future
Immunoterapia di 1 linea Evidenze e Prospettive Future Sara Pilotto Oncologia Medica, Dipart. di Medicina, Università di Verona, A.O.U.I. Verona sara.pilotto@univr.it Negrar, 30 ottobre 2018 Disclosures
More informationMetastasectomy for Melanoma What s the Evidence and When Do We Stop?
Metastasectomy for Melanoma What s the Evidence and When Do We Stop? Vernon K. Sondak, M D Chair, Moffitt Cancer Center Tampa, Florida Focus on Melanoma London, UK October 15, 2013 Disclosures Dr. Sondak
More informationAACR 2018 Investor Meeting
AACR 218 Investor Meeting April 16, 218 1 Forward-Looking Information This presentation contains statements about the Company s future plans and prospects that constitute forward-looking statements for
More informationNivolumab: esperienze italiane nel carcinoma polmonare avanzato
NSCLC avanzato: quali novità nel 2018? Negrar, 30 Ottobre 2018 Nivolumab: esperienze italiane nel carcinoma polmonare avanzato Francesco Grossi UOC Oncologia Medica Fondazione IRCCS Ca Granda Ospedale
More informationArray BioPharma Second Quarter of F2018 Update FEBRUARY 6, 2018
Array BioPharma Second Quarter of F2018 Update FEBRUARY 6, 2018 SAFE HARBOR STATEMENT Forward-looking statements made in the course of this presentation are made pursuant to the safe harbor provisions
More informationImmunotherapy for the Treatment of Head and Neck Cancers. Robert F. Taylor, MD Aurora Health Care
Immunotherapy for the Treatment of Head and Neck Cancers Robert F. Taylor, MD Aurora Health Care Disclosures No relevant financial relationships to disclose I will be discussing non-fda approved indications
More informationImmune Checkpoint Therapy Toxicities: Lessons learned and new strategies to improve outcomes
Immune Checkpoint Therapy Toxicities: Lessons learned and new strategies to improve outcomes Geoffrey T. Gibney, MD Associate Professor Co-leader, Melanoma Disease Group Lombardi Comprehensive Cancer Center
More informationConversations in Oncology. November Kerry Hotel Pudong, Shanghai China
Conversations in Oncology November 12-13 Kerry Hotel Pudong, Shanghai China Immunotherapy of Lung Cancer Professor Caicun Zhou All materials are for scientific exchanges. Afatinib and nintedanib are not
More informationPrinciples and Application of Immunotherapy for Cancer: Advanced Melanoma
In Partnership With Principles and Application of Immunotherapy for Cancer: Advanced Melanoma This program is supported by educational grants from Genentech and Merck. About These Slides Users are encouraged
More informationRenal Cell Carcinoma: Systemic Therapy Progress and Promise
Renal Cell Carcinoma: Systemic Therapy Progress and Promise Michael B. Atkins, M.D. Deputy Director, Lombardi Comprehensive Cancer Ctr Georgetown University Medical Center Everolimus Rini, Campbell, Escudier.
More informationBeyond BRAFi/MEKi: Combination and Sequencing Approaches for in Patients with Metastatic BRAF V600 Mutant Melanoma:
Beyond BRAFi/MEKi: Combination and Sequencing Approaches for in Patients with Metastatic BRAF V600 Mutant Melanoma: Michael B. Atkins, M.D. Deputy Director Georgetown-Lombardi Comprehensive Cancer Center
More information